Patents
Literature
2 results about "Hematopoietic growth factor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hematopoietic growth factor is a group of glycoproteins that causes blood cells to grow and mature (Haematopoiesis). "A group of at least seven substances involved in the production of blood cells, including several interleukins and erythropoietin."
NK cells or T cells expressing chimeric hematopoietic growth factor receptor and their usage
PendingCN122094708APolypeptide with localisation/targeting motifImmunoglobulin superfamilyNatural Killer Cell Inhibitory ReceptorsHematopoietic growth factor
Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Stimulation of hematopoiesis and stem cell engraftment by senolysis
PCT designated stageWO2026050294A1Skeletal/connective tissue cellsMammal material medical ingredientsHematopoietic growth factorStem cell mobilization
Means, methods, and compositions of matter for accelerating hematopoiesis and / or stem cell engraftment through induction of senolysis and / or deactivation of senescent cells. Senolytic agents can be administered together with hematopoietic growth factors. Resistance to stem cell mobilization can be accomplished by removal of senescent cells through senolytic and / or senescence inactivating approaches.
Owner:IMMORTA BIO INC